Physician profile
Andrew Marlowe
NPI 1215985247
$11,999.61
in general payments reported to CMS, 2019-2025
36 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 77% of Otology & Neurotology providers received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $907 · 2021: $2,690 · 2022: $1,169 · 2023: $1,523 · 2024: $2,025 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,534 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,533.99 |
| Education | $154.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,877.60 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,184.64 | 2020-2021 | |
| Amgen INC. | $1,060.04 | 2019-2025 | Tepezza, Uplizna, Tavneos |
| Genzyme Corporation | $969.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $784.46 | 2019-2025 | Dupixent |
| Pfizer INC. | $696.26 | 2023-2025 | |
| Merz North America, INC. | $680.93 | 2019-2023 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $534.68 | 2019-2022 | |
| Optinose US, INC. | $469.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $385.13 | 2021-2025 | Nucala |
| Phathom Pharmaceuticals, INC. | $383.56 | 2024-2025 | Voquezna |
| Stryker Corporation | $350.41 | 2019-2025 | Xpress Loprofile |
| Lilly USA, LLC | $323.19 | 2020-2024 | Emgality, Reyvow |
| Lundbeck LLC | $307.39 | 2020-2025 | Vyepti |
| Med-El Corporation | $290.70 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $241.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $198.44 | 2019-2021 | |
| Advanced Bionics, LLC | $177.76 | 2020-2025 | Hires Ultra Ci Hifocus Ms Electrode |
| Biohaven Pharmaceutical Holding Company LTD. | $168.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $136.94 | 2023-2024 | |
| Kerecis Limited | $136.70 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Neurent Medical Limited | $105.37 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Alk-Abello, INC | $101.43 | 2020-2022 | |
| Acclarent, INC | $92.69 | 2019-2024 | Trudi Nav Cable |
| Allergan, INC. | $63.32 | 2020 | |
| Vertical Pharmaceuticals, LLC | $47.36 | 2023-2024 | Dsuvia |
| Photonicare INC | $41.12 | 2025 | Otosight Middle Ear Scope |
| Merck Sharp & Dohme LLC | $39.25 | 2020-2023 | |
| Hikma Pharmaceuticals USA | $33.86 | 2023 | Ryaltris |
| Medtronic, INC. | $26.64 | 2025 | Nuvent |
| Paratek Pharmaceuticals, INC. | $17.43 | 2025 | Xhance |
| Smith+Nephew, INC. | $17.23 | 2021 | |
| Ambu INC. | $16.97 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.67 | 2019 | |
| Ethicon US, LLC | $13.03 | 2019 | |
| Zyla Life Sciences, INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Marlowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.